SIPO rejects Sovaldi patent as Chinese regulators turn attention to drug prices
China's State Intellectual Property Office (SIPO) last week rejected a patent application related to the hepatitis C drug Sovaldi, which is produced by Gilead Sciences. The US company already owns a Chinese patent on the drug’s main ingredient…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.